BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017:
Credit Suisse 26th Annual Healthcare Conference
November 8, 2017 at 12:20 pm MT
To view the webcast follow this link: INVA at Credit Suisse
Stifel Nicolaus Weisel 2017 Healthcare Conference
November 15, 2017 at 10:15 a.m. ET
New York, NY
To view the webcast follow this link: INVA at Stifel
Both presentations will be available and archived on the investor relations page of the Innoviva web site at: http://investor.inva.com/events.cfm.
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for TRELEGY® ELLIPTA® and earlier-stage programs partnered with Theravance BioPharma, Inc.. For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.